ICP compared to trimetaphan. No difference in ICP was found with either drug when the patients were hypocapnic. 6 Because of the potentially deleterious effect on intracranial dynamics, it may be unwise to use either SNP, nitroglycerine or diazoxide unless ICP is being monitored, since all of these drugs have been shown to cause increases in ICP. 2 > 3 - 6 -8 It is unclear to us whether the patients who do poorly with HTE do so because of their disease or treatment. Because of its lack of direct effect on cerebral vessels, 7 trimethephan may be safer to use initially in HTE, as it would not be expected to increase CBV and brain edema and hence ICP.
The author replies:
I agree with Drs. Egol, Snyder, and Grenvik that increased intracra nial pressure (ICP) is a serious factor in hypertensive encephalopathy (HTE). AS indicated in my article, the reversal of the process producing edema requires the reduction of systemic arterial pressure, an urgent measure in the treatment of HTE.
Reported studies of the cerebrovascular effects of sodium nitroprus side (SNP) provide conflicting results. Stullken and Sokoll 1 found no increase in ICP when SNP was administered to normotensive cats, in contrast to trimethaphan which did produce an increase in ICP. Howev er, they found an increase in ICP when vasopressin was given to animals following systemic hypotension induced by either drug. As noted by Marsh 2 studies such as those by Stullken and Sokoll persuaded some anesthetists to change from trimethaphan to SNP for blood pressure control during induction. Other studies [2] [3] [4] have demonstrated elevation in ICP with SNP. Differences in studies undoubtedly result from factors such as species differences, variations in the nature and extent of brain swelling, level of systemic blood pressure, the method of injecting the test drug, extent of blood pressure drop with hypotensive therapy and paCO 2 .
Care and caution must be exercised when administering any of the major hypotensive drugs. They must be used in a setting which enables constant monitoring of vital signs, but I do not agree that attempts should be made to monitor ICP in all patients with HTE. 2 One explanation, expressed in an editorial opinion by Hart and Easton, is that the frequency of stroke due to other causes is low in the younger patients with MVP thereby allowing the relation of stroke to MVP to be clearly seen. Among older persons, they suggest, the stroke associated with MVP is overshadowed by the more frequent occurrence of stroke of all types. 3 We suggest that selective bias is the explanation for the phenomenon, operating in case "selection" in neurological patient series.
A classic study of how a collection of clinical cases reported from a teaching hospital differs from findings derived from a population is that of Crawford and Morris. 4 This feature of a population study rather than a collection of clinical cases obtained through a series of selective referrals, illustrates the way epidemiologic study of disease in populations can help to correct and complete the clinical picture of a disease and its natural history. Once the association of MVP and stroke was detected and confirmed by clinicians a more accurate estimate of the true frequency of MVP and of subsequent stroke risk will probably be obtained by systematic longitu dinal study in a defined population. Such a prospective investigation is underway in the Framingham Study. 5 It is quite likely that the reported coincidences of stroke and MVP in young stroke victims without evidence of carotid and other predisposing cardiac lesions are exaggerated. Under these circumstances MVP would be intensively sought out. By contrast, in MVP cases, which are com monly encountered in cardiology practice, strokes are seldom encoun tered, more likely reflecting the true situation. Changes in hematocrit and blood viscosity may induce simultaneous changes in the blood's oxygen release capacity which has to be taken into account. Grotta and coworkers hardly discuss changes in oxygen release capacity in their paper, but seem to consider the effects as largely due to viscosity changes. Thomas on the other hand mentions that there is some debate on the relative importance of blood viscosity and blood oxygen carrying capacity for the flow changes.
Barnett HJM: Embolism in Mitral Valve
First, it should be pointed out that the blood oxygen release capacity is not a simple function of its oxygen binding capacity but is also heavily influenced by shifts of the oxyhemoglobine dissociation curve. Thus, a shift to the left of the oxyhemoglobin dissociation curve results in a higher oxygen saturation at a given oxygen tension and less oxygen can then be released in the tissue if its oxygen tension has to be maintained unchanged. A shift to the left of the oxyhemoglobine dissociation curve, thus results in a CBF increase. 3 Changes in hematocrit result in blood viscosity, in oxygen release capacity and in CBF changes. The oxygen tension in jugular venous blood remains constant following acute de crease of the hematocrit in patients with normal or with high hemato crit. 3 . 4 Here the oxyhemoglobine dissociation curve also remains con stant. But, in patients with chronic changes in hematocrit it is known to shift; e.g. to the right in anaemia.
Grotta and coworkers performed multivariable analysis and demon strated that the serum fibrinogen concentration in addition to the hema tocrit seems of importance for the CBF. They interpreted this to changes in viscosity which very well may be the case. However, as the oxy hemoglobine dissociation curve is shifted to the right in anaemia, this would per se result in a slightly lower CBF. If such data had been available their multivariable analysis of fibrinogen concentration and hematocrit might well have yielded another result. Thus, caution must be exercised in the interpretation of these results.
